2024 – Page 6 – Talk Bio

Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends

9 months ago talkbio0Tagged alpha-Synuclein, PADOVA study, Parkinson 's disease, Phase 2b Trial, Prasinezumab, Prothena, Roche (company)

Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study

Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends

9 months ago talkbio0Tagged Clinical Trials, exploration, Failure (biologic function), Parkinson 's disease, Prasinezumab, Roche (company), trends qualifier

Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration

Ring Therapeutics Undergoes Significant Restructuring, Laying Off Nearly Half of Its Workforce

9 months ago talkbio0Tagged Industry, restructuring, Ring (shape)

Ring Therapeutics, layoffs, workforce reduction, biotech industry, restructuring

Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases

9 months ago talkbio0Tagged cardiometabolic diseases, Nordisk, PHICS, proximity-based, research collaboration, Technology

Novo Nordisk, Photys Therapeutics, Cardiometabolic diseases, Proximity-based therapeutics, PHICS technology, Research collaboration

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

9 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Biotechnology, Clinical Development, Cornea, Corneal endothelial dysfunction, Edema, Phase 2 Clinical Trials, Vision

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development

Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal

9 months ago talkbio0Tagged GLP-1 receptor, Hansoh Pharma, Merck & Co., Obesity, Oral cavity, Partnership, pharmaceutical collaboration

Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership

SiteOne Therapeutics Secures $100M Series C Funding to Advance Non-Opioid Pain Treatments

9 months ago talkbio0Tagged Non-Opioid Pain, Peripheral Nervous System, sensory hyperexcitability disorders, Series, SiteOne Therapeutics

Non-opioid pain treatments, SiteOne Therapeutics, Series C funding, ion channel modulators, peripheral nervous system (PNS), sensory hyperexcitability disorders.

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

9 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

9 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology

Novo Holdings Spearheads $100M Series C Financing for SiteOne Therapeutics to Develop Non-Opioid Pain Therapies

9 months ago talkbio0Tagged Holdings, ion channel modulators, Non-Opioid Pain, Opioid Epidemic, pain chronic management, Peripheral Nervous System, Series C financing, SiteOne Therapeutics

Novo Holdings, SiteOne Therapeutics, Non-opioid pain treatments, Series C financing, Ion channel modulators, Peripheral nervous system (PNS) pain treatments, Chronic pain management, Opioid epidemic